DRRX has been granted a new patent
Dec 25, 2024, 11:32 PM
-13.42%
What does DRRX do
DURECT, based in Cupertino, California, develops investigational therapies, including Larsucosterol for alcohol-associated hepatitis. Its FDA-approved products include POSIMIR and PERSERIS, while employing 48 staff since its 2000 IPO.
DRRX filed a patent for "25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and uses of same" on Fri, December 23, 2022.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.